We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Immunicon and Diagnostic Hybrids Sign Distribution Agreement

By HospiMedica staff writers
Posted on 19 Jan 2007
Immunicon Corporation and Diagnostic Hybrids (DHI, Athens, OH, USA) signed a definitive license, development, supply, and distribution agreement to develop and commercialize products in the field of clinical virology diagnostics, starting with a panel of multiplex respiratory virus and sexually transmitted infection assays. More...
Financial and other details of the agreement were not disclosed.

Byron Hewett, president and chief executive officer of Immunicon commented, We are excited about this collaboration. The clinical virology market is a natural extension for our enrichment technologies and rare cell analysis platforms beyond our current presence in cancer. By combining DHI's expertise in viral antigen detection and specimen processing with our technologies, we expect to deliver highly sensitive, rapid assays where there is currently a significant and unmet medical need.

The clinical virology product portfolio will be developed for Immunicon's EasyCount system, which is a small, automated analyzer based on fluorescence microscopy. Immunicon and DHI believe that a variety of virus detection kits with multi-target identification capability can be developed with sensitivity superior to current rapid methods, possibly approaching performance of culture-based and molecular tests. The definitive respiratory virus culture testing can require up to two days and most polymerase chain reaction (PCR)-based tests are either commercially unavailable for certain viruses or hospital laboratories do not have the technical staff and specialized equipment required to develop home-brew assays.

David Scholl, Ph.D., president and chief executive officer of DHI commented, Our innovative approach to cell-based diagnostic products has created strong customer relationships with clinical virologists. For example, Elvis and the MixedCells product lines have made high sensitivity test results for herpes and the seven major respiratory viruses possible in 16-48 hours. We believe that Immunicon's EasyCount System and proprietary ferrofluid technology may offer automated, reliable, and easily interpreted results with sensitivity close to gold standard cell culture assays and much faster.



Related Links:
Immunicon
Diagnostic Hybrids

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.